Japanese Pharmaceutical Market, 2006-2011

Executive Summary

The Japanese pharmaceutical market is the second largest individual market and with sales of $60 billion constitutes approximately 11% of the world market. However, it is a market that frustrates the major pharmaceutical companies as it is growing at a significantly lower rate of growth than the average of the world pharmaceutical markets.
Historically this has been attributed to the struggling Japanese economy, but more recently the biennial NHI drug price reductions have been the determining factor of the Japanese pharmaceutical market. As the Japanese government seeks to stimulate further industrial growth, it must adopt policies that also continue to restrict the overall health expenditure.
Pivotal period of change.

The Japanese pharmaceutical market is entering a pivotal period of change. Although it is unlikely to see high growth before 2011, visiongain expects significant company activity as Japanese pharmaceutical companies strive towards international competitiveness. Global pharmaceutical companies have already begun to take advantage of the changing regulatory and economic conditions in Japan. The following five years will see further mergers and acquisitions as already demonstrated by the leading companies within Japan.

The Leading Pharmaceutical Companies Within Japan

1. Takeda
2. Astellas
3. Daiichi Sankyo
4. Pfizer
5. Roche (Chugai)
6. Eisai
7. Dainippon Sumitomo
8. Novartis
9. Taisho
10. Mitsubishi Pharma

Why you should buy this report

• The Japanese market is worth $60 billion and the major pharmaceutical companies are seeking greater return from their investments.
• Key companies are examined, recent histories summarised and strategies outlined to provide indications of potential strengths.
• Detailed analysis of the Japanese reimbursement system. The Japanese patent system is outlined.
• This report considers the latest financial and anecdotal information from the Japanese pharmaceutical market to enable the most accurate assessment of the medium-term future of the $60 billion market.